|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide |
Synonyms ![]() |
compound 8 [PMID: 20143778] | CUDC101 |
Database Links ![]() |
|
BindingDB Ligand | 50307768 |
CAS Registry No. | 1012054-59-9 (source: PubChem) |
ChEMBL Ligand | CHEMBL598797 |
GtoPdb PubChem SID | 310264675 |
PubChem CID | 24756910 |
Search Google for chemical match using the InChIKey | PLIVFNIUGLLCEK-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | PLIVFNIUGLLCEK |
Search UniChem for chemical match using the InChIKey | PLIVFNIUGLLCEK-UHFFFAOYSA-N |
Search UniChem for chemicals with the same backbone | PLIVFNIUGLLCEK |
Comments |
CUDC-101 is an orally available Phase I compound which is multiacting, inhibiting class I/II histone deacetylases (HDACs) but not the class III sirtuins, and the type I receptor tyrosine kinases EGFR and ERBB2 (HER2) [1]. Targeting two pathogenic pathways simultaneously is one of the strategies being evaluated to overcome problems associated with molecular heterogeneity of tumours and the development of drug resistance. |